82463-30-7

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dichloro-5-methyl-quinoxaline is used as a key intermediate in the synthesis of various pharmaceuticals for its potential role in the development of new drugs. Its unique structure allows for the creation of diverse medicinal compounds with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2,3-dichloro-5-methyl-quinoxaline is utilized as an intermediate in the production of pesticides and other agrochemicals. Its chemical properties make it suitable for the development of compounds that can effectively control pests and diseases in agriculture.
Used in Dye Industry:
2,3-dichloro-5-methyl-quinoxaline is also employed as a building block in the synthesis of dyes. Its structural features contribute to the creation of dyes with specific color properties and stability, which are used in various applications such as textiles, plastics, and printing inks.
Overall, the versatile nature of 2,3-dichloro-5-methyl-quinoxaline makes it a valuable compound in the manufacturing of a wide range of products across different industries, including pharmaceuticals, agriculture, and dyes.

Upstream product

• 61875-33-0 5-methylquinoxaline-2,3-diol 
• 2687-25-4 3-methyl-1,2-benzenediamine 

Downstream Products

• 1359979-07-9 1-(3,5-dimethoxyphenyl)-4-[(3-methoxy-5-methylquinoxalin-2-yl)aminocarbonyl]piperazine 
• 1359979-06-8 1-(3,5-dimethylphenyl)-4-[(3-methoxy-5-methylquinoxalin-2-yl)aminocarbonyl]piperazine 

Relevant academic research and scientific papers

HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE

The present invention relates to compounds of formula (I), wherein R1 to R3, A and Q are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE

The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

A One-pot Facile Synthesis of 2,3-Dihydroxyquinoxaline and 2,3-Dichloroquinoxaline Derivatives Using Silica Gel as an Efficient Catalyst

An efficient one-pot reaction has been developed for the synthesis of 2,3-dichloroquinoxaline derivatives 3a–n. The reaction was performed in two steps via a silica gel catalyzed tandem process from o-phenylenediamine and oxalic acid, followed by addition of phosphorus oxychloride (POCl3). A variety of 2,3-dichloroquinoxalines have been obtained in good to excellent overall yields. Eight known compounds 3a–3h were characterized by IR, 1H-NMR, and mass spectroscopies. Compounds 3i–3n without spectroscopic data were characterized by IR, 1H-NMR, 13C-NMR, and mass spectroscopies.

Method for preparing 2,3-dichloro-quinoxaline derivative through one-pot procedure

The invention belongs to the field of drug synthesis, and specifically relates to a new method for preparing 2,3-dichloro-quinoxaline derivative through one-pot procedure. According to the method, cheap o-phenylenediamine and oxalic acid are adopted as raw materials, and the cheap and easily available and environmentally friendly silica gel or methanesulfonic acid is adopted as a catalyst while steps of intermediate separation and purification are omitted; the method has the advantages of easiness in operation, low cost, mild reaction conditions and environmental friendliness and promotes industrial mass production.

FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY

The present invention relates to certain certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the "Fused Tricyclic Compounds"), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.